medigraphic.com
Instituto Nacional de Salud Pública

2015, Number 6

<< Back Next >>

salud publica mex 2015; 57 (6)

Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model

Pichon-Riviere A, Alcaraz A, Caporale J, Bardach A, Rey-Ares L, Klein K, Calderón M, Augustovski F, Tatti S

Language: Spanish
References: 49
Page: 504-513
PDF size: 263.02 Kb.


ABSTRACT

Objective. To assess the cost-effectiveness of the quadrivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective. Materials and methods. A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs. Results. Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results. Conclusions. Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.


REFERENCES

  1. Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 Suppl 3:1-10.

  2. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased longterm risk of cervical cancer. J Natl Cancer Inst 2011;103(18):1387-1396.

  3. Abba MC, Gomez MA, Golijow CD. Human papillomavirus genotype distribution in cervical infections among woman in La Plata, Argentina. Rev Argent Microbiol 2003;35(2):74-79.

  4. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7(7):453-459.

  5. Matos E, Loria D, Amestoy GM, Herrera L, Prince MA, Moreno J, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003;30(8):593-599.

  6. Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi M. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: Systematic review and meta-analysis. PLoS ONE 2011;6(10):1-10.

  7. Datos del Sistema de Vigilancia y Reporte del Instituto Nacional del Cancer en base a registros de mortalidad de la Dirección de Estadistica e Información en Salud. Argentina: Ministerio de Salud de la Nación, 2012 [consultado el 1 de enero de 2015]. Disponible en: http://www.msal.gov. ar/inc/index.php/acerca-del-cancer/estadisticas

  8. Jorrat JR. Información, actitudes y conductas en relación con el VIH/ sida: estudio social en población bajo la línea de pobreza en el área metropolitana de Buenos Aires. Buenos Aires, Argentina: Ubatec SA, 2008 [consultado el 1 de octubre de 2014. Disponible en: http://www.ubatec. uba.ar/fondomundial/downloads/publicaciones/invPOB.pdf

  9. Jemal A, Vineis P, Bray F, Torre L, Forman D. The Cancer Atlas. Atlanta: American Cancer Society, 2014 [Consultado el 1 de julio de 2015]. Disponible en: http://es.scribd.com/doc/258178255/The-Cancer-Atlas- 2nd-Edition - scribd

  10. Abriata M. Cáncer en Argentina 2001-2011. Rev Argent Salud Pública 2013;4(16):39-45.

  11. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez- Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.

  12. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against highgrade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369(9574):1693-1702.

  13. Programa Nacional de Control de Enfermedades Inmunoprevenibles. Argentina: Ministerio de Salud de la Nación; 2013 [consultado el 1 de enero de 2015]. Dispobnible en: http://www.msal.gov.ar/index.php/ programas-y-planes/51-programa-nacional-de-control-de-enfermedades- inmunoprevenibles

  14. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008;115(8):947-956.

  15. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH. The costeffectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev 2008;9(3):459-466.

  16. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28(42):6858-6867.

  17. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13(1):28-41.

  18. Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol 2008;70(8):2126-2176.

  19. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16(2):231-250.

  20. Estadísticas Vitales. Información Básica. Buenos Aires: Argentina. Ministerio de Salud de la Nación. Dirección de Estadística e Información en Salud (DEIS) 2010 [consultado el 1 de enero de 2015]. Disponible en: http://www.deis.gov.ar/Publicaciones/Archivos/Serie5Nro54.pdf

  21. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010 [consultado el 1 de diciembre de 2014]. Disponible en: http://globocan.iarc.fr/agespecific_table_r_html.asp?selection=503 2&title=Argentina&sex=2&type=0&stat=0&window=1&sort=0&su bmit=%A0Execute%A0

  22. Syrjanen K, Naud P, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, et al. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. Anticancer Res 2005;25(5):3469-3480.

  23. Encuesta Nacional de Factores de Riesgo. Argentina: Ministerio de Salud de la Nación 2009 [consulado el 1 de enero de 2015]. Disponible en: http://www.msal.gov.ar/fesp/descargas_home/seg_encuesta_ nac_factores_riesgo_2011.pdf.

  24. Sarian LO, Derchain S, Shabalova I, Tatti S, Naud P, Longatto-Filho A, et al. Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe. J Med Screen 2010;17(4):195-203.

  25. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005;93:575-581.

  26. Flannelly G, Langhan H, Jandial L, Mana E, Campbell M, Kitchener H. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1997;104:718-722.

  27. Sepúlveda P, González F, Napolitano C, Roncone E, Cavada G. Cancer de cuello uterino: sobrevida a 3 y 5 años en Hospital San Jose. Rev Chil Obstet Ginecol 2008;73(3):151-154.

  28. Castellsague X, Muñoz N, Saah A. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. BJC. 2011;105(1):28-37.

  29. Muñoz N. Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. JNCI 2010;102(5):135-139.

  30. Colantonio L, Gomez JA, Demarteau N, Standaert B, Pichon-Riviere A, Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009;27(40):5519-5529.

  31. Programa Ampliado de Inmunizaciones. Precios de las Vacunas 2013 [consultado el 1 de enero de 2015]. Disponible en: http://www.paho. org/hq/index.php?option=com_docman&task=doc_download&gid =19890&Itemid=270&lang=es

  32. Gold M, Franks P, McCoy K, Fryback D. Toward consistency in costutilities analysis. Med Care 1998;36:778-792.

  33. Myers E, Green S, Lipkus I. Pateint preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. Paper presented at: 21st International Papillomavirus Conference 2004; Mexico City, Mexico.

  34. Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D. Quality of life in long-term cervical cancer survivors. Gynecol Oncol 2005;97(2):310-317.

  35. Censo 2010. Total del país. Población por sexo, tasa de variación intracensal, según provincia. Años 2001-2010. Buenos Aires, Argentina: Instituto Nacional de Estadísticas y Censos (INDEC), 2010 [consultado el 1 de enero de 2015]. Disponible en: http://web2.cba.gov.ar/actual_web/ estadisticas/censo2010/index.htm.

  36. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. Human papillomavirus and related diseases in country. 2015 [consultado el 1 de enero de 2015]. Disponible en: http://www.hpvcentre.net/ dataquery.php

  37. Petracci M. Argentina, derechos humanos y sexualidad 2007 [consultado el 1 de enero de 2015]. Disponible en: http://www. clacaidigital.info:8080/xmlui/bitstream/handle/123456789/78/ Derechoshumanosysexualidad-argentina-pdf.pdf?sequence=1 Consultado:01/01/2015.

  38. Linetzky B, Morello P, Virgolini M, Ferrante D. Resultados de la Primera Encuesta Nacional de Salud Escolar. Argentina, 2007. Arch Argent Pediatr 2011;109(2):111-116.

  39. Barrionuevo A, Martinez A, Casé M, Manrique M, Brú S, Tarrazó S, et al. Factores de riesgo y cáncer de cuello uterino. Argentina: Programa Provincial de Prevención y Detección Precoz de Cáncer de Cuello Uterino y Mama; 2003 [consultado el 1 de enerod e 2015]. Disponible en: http://pap. mendoza.gov.ar/modules.php?name=News&file=article&sid=67.

  40. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007;26(1):128-139.

  41. Resultados de la Encuesta Nacional de Salud Sexual 2009. España: Ministerio de Sanidad y Política Social; Observatorio de Salud de la Mujer de la Agencia de Calidad del Sistema Nacional de Salud, 2009 [consultado el 1 de diciembre de 2014]. Disponible en: http://www. msc.es/organizacion/sns/planCalidadSNS/docs/v5_presentacion_ ResultadosENSS_16dic09.pdf.

  42. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007;97(9):1322-1328.

  43. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC public health 2009;9:401.

  44. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14(2):244-251.

  45. Barnabas V, Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoecon Outcomes Res 2007;7(3):251-267.

  46. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. Jama 2003;290(6):781-789.

  47. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359(8):821-832.

  48. Banco Mundial de Salud. Datos de PBI per cápita de Argentina, 2013 [consultado el 1 de enero de 2015]. Disponible en: http://data.worldbank. org/indicator/NY.GDP.PCAP.CD.

  49. Garland SM, Brown DR. Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. Expert Opin Biol Ther 2014;14(4):527-534.




2020     |     www.medigraphic.com